{"id":"sodium-oligomannate-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal discomfort"}]},"_chembl":{"chemblId":"CHEMBL93268","moleculeType":"Small molecule","molecularWeight":"69.00"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sodium oligomannate is a prebiotic oligosaccharide that selectively promotes the growth of beneficial bacteria in the gut microbiota, particularly Faecalibacterium prausnitzii. This shifts the microbial ecosystem away from pathogenic species and increases the production of short-chain fatty acids, which cross the blood-brain barrier and reduce neuroinflammatory responses implicated in neurodegeneration.","oneSentence":"Sodium oligomannate modulates the gut microbiota and reduces neuroinflammation by altering bacterial composition and metabolite production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:50.357Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT05545605","phase":"NA","title":"Efficacy and Safety of Sodium Oligomannate in the Prevention of PSCI","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2023-04-01","conditions":"Ischemic Stroke","enrollment":116},{"nctId":"NCT05058040","phase":"PHASE4","title":"A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.","startDate":"2021-06-02","conditions":"Alzheimer Disease","enrollment":2500},{"nctId":"NCT05181475","phase":"PHASE4","title":"Long-term Efficacy and Safety Study of GV-971","status":"ACTIVE_NOT_RECRUITING","sponsor":"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.","startDate":"2021-12-07","conditions":"Alzheimer Disease","enrollment":800},{"nctId":"NCT05430867","phase":"PHASE4","title":"Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-07-01","conditions":"Treatment, Efficacy, Safety","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Sodium Oligomannate Capsules","genericName":"Sodium Oligomannate Capsules","companyName":"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.","companyId":"green-valley-shanghai-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sodium oligomannate modulates the gut microbiota and reduces neuroinflammation by altering bacterial composition and metabolite production. Used for Mild to moderate Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}